Skip to main content

Penumbra Inc

For the period ended Dec 31, 2024. Filed Feb 18, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 18, 2025

PEN$321.85+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 9B. Other Information

Rule 10b5-1 Trading Plans

During the quarterly period ended December 31, 2024, certain of our directors and officers adopted trading plans, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (the “Rule 10b5-1 Trading Arrangements”). Each Rule 10b5-1 Trading Arrangement was entered into during an open trading window under our Securities Trading Policy. The following table presents the material terms of each Rule 10b5-1 Trading Arrangement adopted by our officers and directors during the three months ended December 31, 2024, other than terms with respect to the price at which the individual executing the Rule 10b5-1 Trading Arrangement is authorized to trade:

Name and Title of Officer or DirectorPlan ActionPlan Action DatePlan DurationTotal Securities to be Sold
Arani Bose, DirectorAdoption11/21/20243/3/2025 - 8/29/202548,000
Adam Elsesser, Chairman, Chief Executive Officer and PresidentAdoption11/25/20243/5/2025 - 9/3/2025Indeterminable(1)
Don Kassing, DirectorAdoption11/4/20244/1/2025 - 11/1/2025498
Bridget O'Rourke, DirectorAdoption11/11/20243/3/2025 - 8/11/2025250
Johanna Roberts, Executive Vice President, General Counsel and SecretaryAdoption11/26/20243/3/2025 - 12/31/20259,000
Lambert Shiu, Chief Accounting OfficerAdoption11/27/20243/3/2025 - 3/31/20257,789
Thomas Wilder, DirectorAdoption11/14/20243/31/2025 - 11/28/2025720
Maggie Yuen, Chief Financial OfficerAdoption11/29/20243/3/2025 - 11/7/20256,000

(1) The plan provides for the sale of (i) up to 45,000 shares of our common stock to be acquired upon the exercise of stock options, and (ii) an undetermined number of shares of common stock, pursuant to sell-to-cover transactions, necessary to satisfy the exercise price and tax withholding requirements upon the exercise of up to 405,000 stock options, with the specific number of shares to be sold being dependent on the market price of our common stock at the time of such transactions.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.